– USA, PA – Seneca Therapeutics, Inc., today announced the appointment of Cuong Do to its Board of Directors.
“Cuong has successfully financed and led several life science biotech companies across a range of therapeutic areas, and we are extremely excited to welcome him to our Board. Cuong’s extensive executive leadership experience, together with his strategic expertise, will help guide us as we advance our neuroendocrine neoplasm cancer programs toward late-stage trials. He will also work to deepen our relationships with leading biopharmaceutical companies. His background is extremely complementary to those of our leadership team and is strategically aligned with the long-term R&D goals of the company. I look forward to working together,” said CEO, James Hussey.
About Cuong Do
Mr. Do joins STI’s Board with over two decades of experience in the pharmaceutical and biotechnology industries. He is currently CEO of BioVie where he leads a team focused on developing treatments for Alzheimer’s Disease. Prior to his appointment with BioVie, Mr. Do was President of Samsung Electronics Co., Ltd. Global Strategy Group where he helped set the strategic direction for Samsung’s diverse business portfolio. He was previously CSO for Merck and Company, a leading US pharmaceutical company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build health care, high-tech, and corporate finance practices.
He holds a BA from Dartmouth College and an MBA from Dartmouth’s Tuck School of Business.
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV. Further, the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 create additional anti-tumor effects.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.